Management ChangeJul 7, 2026, 04:02 PM
Vor Bio Appoints David Zaccardelli to Board of Directors
AI Summary
Vor Bio announced the appointment of David Zaccardelli, Pharm.D., to its Board of Directors. Dr. Zaccardelli brings over 20 years of biopharmaceutical leadership, having successfully led companies through late-stage development, regulatory approval, and commercial launch, including Verona Pharma and Dova Pharmaceuticals. Concurrently, Andrew Levin, M.D., Ph.D., stepped down from the Board.
Key Highlights
- Vor Bio appointed David Zaccardelli, Pharm.D., to its Board of Directors.
- Dr. Zaccardelli has over 20 years of biopharmaceutical leadership experience.
- He previously served as President and CEO of Verona Pharma, acquired by Merck for $10 billion.
- He also led Dova Pharmaceuticals, acquired by Swedish Orphan Biovitrum for up to $915 million.
- Andrew Levin, M.D., Ph.D., stepped down from Vor Bio's Board of Directors.
Price Impact
More from VOR